210 related articles for article (PubMed ID: 24397195)
1. The role of immunohistochemical evaluation in the diagnosis of malignant mesothelioma of the pleura.
Panjković M; Lovrenski A; Eri Z; Usaj SK; Tegeltija D; Krcedinac J
Vojnosanit Pregl; 2013 Nov; 70(11):1010-4. PubMed ID: 24397195
[TBL] [Abstract][Full Text] [Related]
2. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.
Bateman AC; al-Talib RK; Newman T; Williams JH; Herbert A
Histopathology; 1997 Jan; 30(1):49-56. PubMed ID: 9023557
[TBL] [Abstract][Full Text] [Related]
4. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
Marchevsky AM; LeStang N; Hiroshima K; Pelosi G; Attanoos R; Churg A; Chirieac L; Dacic S; Husain A; Khoor A; Klebe S; Lantuejoul S; Roggli V; Vignaud JM; Weynard B; Sauter J; Henderson D; Nabeshima K; Galateau-Salle F
Hum Pathol; 2017 Sep; 67():160-168. PubMed ID: 28782639
[TBL] [Abstract][Full Text] [Related]
5. h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type.
Comin CE; Dini S; Novelli L; Santi R; Asirelli G; Messerini L
Am J Surg Pathol; 2006 Apr; 30(4):463-9. PubMed ID: 16625092
[TBL] [Abstract][Full Text] [Related]
6. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
7. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours.
Garcia-Prats MD; Ballestin C; Sotelo T; Lopez-Encuentra A; Mayordomo JI
Histopathology; 1998 May; 32(5):462-72. PubMed ID: 9639123
[TBL] [Abstract][Full Text] [Related]
8. Synchronous pulmonary carcinoma and pleural diffuse malignant mesothelioma.
Allen TC; Moran C
Arch Pathol Lab Med; 2006 May; 130(5):721-4. PubMed ID: 16683892
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data.
King JE; Thatcher N; Pickering CA; Hasleton PS
Histopathology; 2006 Feb; 48(3):223-32. PubMed ID: 16430468
[TBL] [Abstract][Full Text] [Related]
10. A case of pleural epithelioid sarcoma of proximal type presenting as malignant pleural mesothelioma.
Madsen GA; Rasmussen TR; Bærentzen S
J Thorac Oncol; 2013 Oct; 8(10):e89-90. PubMed ID: 24457248
[No Abstract] [Full Text] [Related]
11. Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma.
Mansour MSI; Huseinzade A; Seidal T; Hejny K; Maty A; Taheri-Eilagh F; Mager U; Dejmek A; Dobra K; Brunnström H
Cytopathology; 2023 Sep; 34(5):456-465. PubMed ID: 37337638
[TBL] [Abstract][Full Text] [Related]
12. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
[TBL] [Abstract][Full Text] [Related]
13. The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının.
Sahin N; Akatli AN; Celik MR; Ulutas H; Samdanci ET; Colak C
Pathol Oncol Res; 2017 Jul; 23(3):487-491. PubMed ID: 27761727
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary adenocarcinoma simulating malignant mesothelioma.
Tang P; Vatsia SK; Teichberg S; Kahn E
Arch Pathol Lab Med; 2001 Dec; 125(12):1598-600. PubMed ID: 11735699
[TBL] [Abstract][Full Text] [Related]
15. Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma.
Thapa B; Walkiewicz M; Murone C; Asadi K; Deb S; Barnett S; Knight S; Mitchell P; Liew D; Watkins DN; John T
Pathology; 2016 Dec; 48(7):660-665. PubMed ID: 27780599
[TBL] [Abstract][Full Text] [Related]
16. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
17. Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry.
Roberts F; McCall AE; Burnett RA
J Clin Pathol; 2001 Oct; 54(10):766-70. PubMed ID: 11577123
[TBL] [Abstract][Full Text] [Related]
18. Synchronous pleural and peritoneal malignant mesothelioma: a case report and review of literature.
Del Gobbo A; Fiori S; Gaudioso G; Bonaparte E; Tabano S; Palleschi A; Bosari S; Ferrero S
Int J Clin Exp Pathol; 2014; 7(5):2484-9. PubMed ID: 24966960
[TBL] [Abstract][Full Text] [Related]
19. Deciduoid pleural mesothelioma in an adolescent.
Arango-Tomás E; Algar-Algar FJ; Salvatierra Velázquez A
Arch Bronconeumol; 2013 May; 49(5):218-9. PubMed ID: 23265622
[No Abstract] [Full Text] [Related]
20. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
Pan CC; Chen PC; Chou TY; Chiang H
Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
